On February 5, 2024, WuXi AppTec issued the "Further Announcement on Clarifying Matters", indicating that the company's production and operation activities are normal and there are no major changes in daily operations. The company provides a variety of integrated R&D and manufacturing services, and does not have a human genomics business and does not collect human genome data. The company is not affiliated with any ** or its military organizations. Companies are convinced that they do not pose a risk to any country and should not be predefined as a "biotech company of concern" in the draft. The Company will continue to work with the consultants to communicate with the relevant parties in the legislative process of the Draft, the content of which is subject to further consideration and possible changes.
Wuxi AppTec New Drug Development Co., Ltd. was listed on the Shanghai Stock Exchange on May 8, 2018, and its main business is a comprehensive and integrated platform service for the discovery, R&D and production of small molecule chemical drugs. In the national economic industry, it belongs to the major category of scientific research and technical service industry, and the sub-category of research and experimental development; In terms of Shenwan industry classification, it belongs to the major category of medicine and biology and the subcategory of medical services. As of October 25, 2023, the actual controllers of the company are Ge Li (Li Ge), Zhang Zhaohui, and Liu Xiaozhong.
As of 2024-02-02**, the company's share price is 5022 yuan shares, with a circulating market value of 14908.6 billion yuan.
Announcement**: Disclaimer: This article is written by the robot, jointly incubated by Pencil Road and Hanxin Society, and the main data is provided by Hanguang Suwen. The content and data in this article are for reference only and do not constitute investment advice.